Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 11, 2026

Company name:	SHIONOGI & CO., LTD.
Representative:	Isao Teshirogi, Representative Director, President and CEO
Stock Code:	4507 (Prime Market of the Tokyo Stock Exchange)
Contact:	Yoshimasa Kyokawa, Vice President, Corporate Communications Department (TEL.06-6202-2161)

(Corrections / Correction of Numerical Data) Corrections to the Consolidated Financial Results for the First Quarter of Fiscal Year 2026 (IFRS)

SHIONOGI & CO., LTD. hereby announced the following corrections to its “Consolidated Financial Results for the First Quarter of Fiscal Year 2026 (IFRS)” disclosed on August 3, 2026. As numerical data (XBRL) has also been corrected, the corrected numerical data is also sent.

1. Reason for corrections

   Due to errors in part of the content stated on the attachment of the above-mentioned disclosure material released, “1. Overview of Operating Results and Financial Position (3) Cash Flows for the First Quarter of the Fiscal Year Ending March 31, 2027” and “2. Consolidated Financial Statements and Notes (4) Consolidated statement of cash flows”, we hereby issue these corrections.

   These corrections were made due to errors identified in the calculation process of “Dividends received from entities accounted for using equity method,” which has been separately presented since the first quarter of the fiscal year ending March 31, 2027, and in the calculation of cash flows related to the acquisition of the edaravone business. Accordingly, the related items have been corrected.

2. Details of corrections

   The corrected items are underlined.

（Before correction）

1. Overview of Operating Results and Financial Position

(3) Cash Flows for the First Quarter of the Fiscal Year Ending March 31, 2027

Net cash provided by operating activities during the three months ended June 30, 2026 was 43,109 million yen, an increase of 2,065 million yen year on year, due to increases in profit before tax, and depreciation and amortization.

Net cash used in investing activities was 423,731 million yen, an increase of 293,058 million yen year on year, mainly due to payments for acquisition of businesses in connection with the acquisition of the edaravone business from Tanabe Pharma.

Net cash used in financing activities was 34,138 million yen, an increase of 4,757 million yen year on year, mainly due to an increase in cash dividends paid.

As a result, cash and cash equivalents on June 30, 2026 totaled 298,937 million yen, a decrease of 412,459 million yen during the three-month period ended June 30, 2026.

（After correction）

1. Overview of Operating Results and Financial Position

(3) Cash Flows for the First Quarter of the Fiscal Year Ending March 31, 2027

Net cash provided by operating activities during the three months ended June 30, 2026 was 46,318 million yen, an increase of 5,274 million yen year on year, due to increases in profit before tax, and depreciation and amortization.

Net cash used in investing activities was 427,264 million yen, an increase of 296,591 million yen year on year, mainly due to payments for acquisition of businesses in connection with the acquisition of the edaravone business from Tanabe Pharma.

Net cash used in financing activities was 34,138 million yen, an increase of 4,757 million yen year on year, mainly due to an increase in cash dividends paid.

As a result, cash and cash equivalents on June 30, 2026 totaled 298,937 million yen, a decrease of 412,459 million yen during the three-month period ended June 30, 2026.

（Before correction）

2. Consolidated Financial Statements and Notes

(4) Consolidated statement of cash flows

Millions of yen

	Three months ended June 30, 2025	Three months ended June 30, 2026
Cash flows from operating activities		
Profit before tax	46,328	73,736
Depreciation and amortization	5,013	20,880
Share of loss (profit) of investments accounted for using equity method	287	(26,756)
Finance income and finance costs	(12,661)	(9,848)
Decrease (increase) in trade and other receivables	5,874	(2,285)
Decrease (increase) in inventories	(5,458)	(3,063)
Increase (decrease) in trade and other payables	(6,643)	(22,875)
Other	400	3,740
Subtotal	33,141	33,528
Interest and dividends received	22,778	2,257
Dividends received from entities accounted for using equity method	—	28,920
Interest paid	(80)	(1,828)
Income taxes refund (paid)	(14,794)	(19,768)
Net cash provided by (used in) operating activities	41,043	43,109
Cash flows from investing activities		
Payments into time deposits	(67,273)	(39,244)
Proceeds from withdrawal of time deposits	30,018	1,464
Purchase of property, plant and equipment	(4,505)	(4,602)
Purchase of intangible assets	(2,466)	(8,124)
Purchase of investments	(22,272)	(2,306)
Proceeds from sale and redemption of investments	13,000	21,014
Payments for acquisition of businesses	—	(391,877)
Payment for acquisition of shares of equity method affiliates	(76,625)	—
Other	(548)	(56)
Net cash provided by (used in) investing activities	(130,672)	(423,731)

Millions of yen

	Three months ended June 30, 2025	Three months ended June 30, 2026
Cash flows from financing activities		
Repayments of lease liabilities	(927)	(1,183)
Purchase of treasury shares	(0)	(0)
Dividends paid	(28,114)	(32,464)
Dividends paid to non-controlling interests	(337)	(490)
Net cash provided by (used in) financing activities	(29,380)	(34,138)
Effect of exchange rate changes on cash and cash equivalents	(958)	2,300
Net increase (decrease) in cash and cash equivalents	(119,968)	(412,459)
Cash and cash equivalents at beginning of period	374,795	711,397
Cash and cash equivalents at end of period	254,826	298,937

（After correction）

2. Consolidated Financial Statements and Notes

(4) Consolidated statement of cash flows

Millions of yen

	Three months ended June 30, 2025	Three months ended June 30, 2026
Cash flows from operating activities		
Profit before tax	46,328	73,736
Depreciation and amortization	5,013	20,880
Share of loss (profit) of investments accounted for using equity method	287	(26,756)
Finance income and finance costs	(12,661)	(9,848)
Decrease (increase) in trade and other receivables	5,874	(2,285)
Decrease (increase) in inventories	(5,458)	4,969
Increase (decrease) in trade and other payables	(6,643)	(22,875)
Other	400	(758)
Subtotal	33,141	37,061
Interest and dividends received	22,778	7,631
Dividends received from entities accounted for using equity method	—	23,222
Interest paid	(80)	(1,828)
Income taxes refund (paid)	(14,794)	(19,768)
Net cash provided by (used in) operating activities	41,043	46,318
Cash flows from investing activities		
Payments into time deposits	(67,273)	(39,244)
Proceeds from withdrawal of time deposits	30,018	1,464
Purchase of property, plant and equipment	(4,505)	(4,602)
Purchase of intangible assets	(2,466)	(8,124)
Purchase of investments	(22,272)	(2,306)
Proceeds from sale and redemption of investments	13,000	21,014
Payments for acquisition of businesses	—	(391,877)
Payment for acquisition of shares of equity method affiliates	(76,625)	—
Other	(548)	(3,589)
Net cash provided by (used in) investing activities	(130,672)	(427,264)

Millions of yen

	Three months ended June 30, 2025	Three months ended June 30, 2026
Cash flows from financing activities		
Repayments of lease liabilities	(927)	(1,183)
Purchase of treasury shares	(0)	(0)
Dividends paid	(28,114)	(32,464)
Dividends paid to non-controlling interests	(337)	(490)
Net cash provided by (used in) financing activities	(29,380)	(34,138)
Effect of exchange rate changes on cash and cash equivalents	(958)	2,625
Net increase (decrease) in cash and cash equivalents	(119,968)	(412,459)
Cash and cash equivalents at beginning of period	374,795	711,397
Cash and cash equivalents at end of period	254,826	298,937